ISRA MEDICAL JOURNAL p-ISSN: 2073-8285
e-ISSN: 2413-9289
Excellence in Medical Education
الأربعاء 22 ذو الحجة 1441
Wednesday 12th August 2020
Current Issue:
Volume 11 - Issue 6, Nov - Dec 2019
Archives Instructions for Authors Manuscript Submission Review Process Instructions for Reviewer Ahead of Printing Article Tracking
IMJ is recognized by;

- Higher Education Commision of Pakistan (HEC)
- Pakistan Medical & Dental Council (PMDC)

IMJ is Covered by;
- Directory of Open Access scholarly Resources (ROAD)
- EBSCO
- Index Copernicus International (IC Journals Master List)
- Index Medicus for the Eastern Mediterranean Region (IMEMR)
- PakMediNet
- BiblioMed
Title:
Comparison of sofosbuvir, ribavirin plus peg-interferon-α treatment with sofosbuvir plus ribavirin alone in patients with chronic Hepatitis C
Authors:
Zamir Butt, Syed Muhammad Ali Shah, Syed Usama Talat, Muhammad Ajmal, Irfan Younis, Muhammad Afzal
Published on:
2019-12-31
Journal Reference:
Volume 11 - Issue 6     November - December 2019
Pages:
439-443
Download Abstract:
ABSTRACT
 
Objective: To compare the efficacy of weekly Peg-interferon-α, weight based ribavirin and sofosbuvir daily for 12 weeks with weight based ribavirin and sofosbuvir daily for 24 weeks in patients with genotype 3a chronic hepatitis C patients.
Study Design: Cross-sectional analytical comparative study
Place and Duration: Department of Medicine,Aziz Bhatti Shaheed Teaching Hospital Gujrat from November 2015 to July 2017
Methodology: Patients with chronic hepatitis C genotype 3 infection were divided in two equal groups. Group A included patients treated with Peg-interferon-α weekly, weight based ribavirin and sofosbuvir daily for 12 weeks and group B included patients treated with weight-based ribavirin and sofosbuvir daily for 24 weeks.
Results: Each group contained 107(N) patients. Mean age in group A was 42.22+10.66 years compared to 49.66+10.51 years in group B. Early virological response (EVR) was achieved by 98.13% patients in group A compared to 97.2% in group B. End treatment response (ETR) rates were similar in both groups as EVR rates. Sustained virological response at 24 weeks (SVR24) was achieved by 94% patients in group A compared to 90% in group B. Binary logistic regression analysis showed no association of treatment history and presence of cirrhosis with either of EVR, ETR or SVR24 (p>0.05). Significant difference in treatment response with either regimen was not noted.
Conclusion: Dual and triple therapy regimens are equally effective in treating chronic hepatitis C genotype 3 patients.
Keywords: Peg-interferon-α,Sofosbuvir, HCV, Genotype 3, Hepatitis C, Ribavirin,

How to Cite This:


Butt Z, ShahSMA, TalatSU, AjmalM, YounisI, Afzal M. Comparison of sofosbuvir, ribavirin plus peg-interferon-α treatment with sofosbuvir plus ribavirin alone in patients with chronic Hepatitis C.Isra Med J. 2019; 11(6):439-443.


This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.